Advances in molecular biology and their application in the diagnosis and treatment of melanoma;Novedades en biología molecular y su aplicación en el diagnóstico y el tratamiento del melanoma

Actas Dermo-Sifiliograficas

Volumn 100, Issue SUPPL. 1, 2009, Pages 52-65

  Martorell Calatayud, A ^a   Requena, C ^a   Botella Estrada, R ^a   Sangueza O P ^b  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Melanoma; Molecular biology; Pathophysiology; Prognosis; Skin cancer; Treatment

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER DIAGNOSIS; ENVIRONMENTAL FACTOR; HEREDITY; HISTOPATHOLOGY; HUMAN; JUVENILE MELANOMA; MELANOMA; MOLECULAR BIOLOGY; PATHOGENESIS; REVIEW;

EID: 75449099349     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/S0001-7310(09)73168-0     Document Type: Article

References (110)

1. W.H. Clark Jr, D.E. Elder, D. Guerry IV, M.N. Epstein, M.H. Greene, and M.A. Van Horn Study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma Hum Pathol 15 1984 1147 1165
2. M. Takata, Y. Goto, N. Ichii, M. Yamaura, H. Murata, and H. Koga Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas J Invest Dermatol 125 2005 318 322 (Pubitemid 41648166)
3. L. Zhuang, C.S. Lee, R.A. Scolyer, S.W. McCarthy, A.A. Palmer, and X.D. Zhang Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma J Clin Pathol 58 2005 1163 1169 (Pubitemid 41566460)
4. Y. Chudnovsky, A.E. Adams, P.B. Robbins, Q. Lin, and P.A. Khavari Use of human tissue to assess the oncogenic activity of melanoma-associated mutations Nat Genet 37 2005 745 749 (Pubitemid 41754892)
5. K.P. Hoeflich, D.C. Gray, M.T. Eby, J.Y. Tien, L. Wong, and J. Bower Oncogenic BRAF is required for tumor growth and maintenance in melanoma models Cancer Res 66 2006 999 1006 (Pubitemid 43165968)
6. M. Libra, G. Malaponte, P.M. Navolanic, P. Gangemi, V. Bevelacqua, and Proietti. Analysis of BRAF mutation in primary and metastatic melanoma Cell Cycle 4 2005 1382 1384 (Pubitemid 41437127)
7. J.L. Maldonado, J. Fridlyand, H. Patel, A.N. Jain, K. Busam, T. Kageshita, et al. Determinants of BRAF mutations in primary melanomas J Natl Cancer Inst 95 2003 1878 1890
8. P.M. Pollock, U.L. Harper, K.S. Hansen, L.M. Yudt, M. Stark, and C.M. Robbins High frequency of BRAF mutations in nevi Nat Genet 33 2003 19 20 (Pubitemid 36068675)
9. P. Uribe, I.I. Wistuba, and S. González BRAF mutation: A frequent event in benign, atypical, and malignant melanocytic lesions of the skin Am J Dermatopathol 25 2003 365 370 (Pubitemid 37169463)
10. M. Daniotti, M. Oggionni, T. Ranzani, V. Vallacchi, V. Campi, and D. Di Stasi BRAF alterations are associated with complex mutational profiles in malignant melanoma Oncogene 23 2004 5968 5977 (Pubitemid 39093541)
11. R. Kumar, S. Angelini, E. Snellman, and K. Hemminki BRAF mutations are common somatic events in melanocytic nevi J Invest Dermatol 122 2004 342 348 (Pubitemid 38281054)
12. M. Shinozaki, A. Fujimoto, D.L. Morton, and D.S. Hoon Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas Clin Cancer Res 10 2004 1753 1757 (Pubitemid 38435567)
13. M.J. Garnett, and R. Marais Guilty as charged: B-RAF is a human oncogene Cancer Cell 6 2004 313 319 (Pubitemid 39361432)
14. Y. Chudnovsky, A.E. Adams, P.B. Robbins, Q. Lin, and P.A. Khavari Use of human tissue to assess the oncogenic activity of melanoma-associated mutations Nat Genet 37 2005 745 749 (Pubitemid 41754892)
15. P. Uribe, I.I. Wistuba, and S. González Allelotyping, Microsatellite Instability, and BRAF Mutation. Analyses in common and atypical melanocytic nevi and primary cutaneous melanomas Am J Dermatopathol 31 2009 354 363
16. L. Chin, G. Merlino, and R.A. DePinho Malignant melanoma: modern black plague and genetic black box Genes Dev 12 1999 3467 3481 (Pubitemid 28553239)
17. T. Papp, H. Pemsel, R. Zimmermann, R. Bastrop, D.G. Weiss, and D. Schiffmann Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in humancongenital melanocytic naevi J Med Genet 36 1999 610 614 (Pubitemid 29368901)
18. M. Jafari, T. Papp, S. Kirchner, U. Diener, D. Henschler, G. Burg, et al. Analysis of ras mutations in human melanocytic lesions: activation of the ras gene seems to be associated with the nodular type of human malignant melanoma J Cancer Res Clin Oncol 121 1995 23 30
19. A. Van Elsas, S.F. Zerp, S. van der Flier, K.M. Kruse, C. Aarnoudse, and Hayward. Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma Am J Pathol 149 1996 883 893 (Pubitemid 26334172)
20. B.C. Bastian, P.E. LeBoit, and D. Pinkel Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features Am J Pathol 157 2000 967 972 (Pubitemid 32109388)
21. N. Bardeesy, B.C. Bastian, A. Hezel, D. Pinkel, R.A. DePinho, and L. Chin Dual inactivation of RB and p53 pathways in RAS-induced melanomas Mol Cell Biol 21 2001 2144 2153 (Pubitemid 32479635)
22. N.E. Sharpless, K. Kannan, J. Xu, M.W. Bosenberg, and L. Chin Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo Oncogene 22 2003 5055 5059 (Pubitemid 37026403)
23. J. Ackermann, M. Frutschi, K. Kaloulis, T. McKee, A. Trumpp, and F. Beermann Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background Cancer Res 65 2005 4005 4011 (Pubitemid 40775636)
24. J.F. Thompson, R.A. Scolyer, and R.F. Kefford Cutaneous melanoma Lancet 365 2005 687 701
25. A. Kamb, N.A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harshman, and S.V. Tavtigian A cell cycle regulator potentially involved in genesis of many tumor types Science 264 1994 436 440 (Pubitemid 24986726)
26. T. Nobori, K. Miura, D.J. Wu, A. Lois, K. Takabayashi, and D.A. Carson Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers Nature 368 1994 753 756 (Pubitemid 24153417)
27. J.F. Flores, G.J. Walker, J.M. Glendening, F.G. Haluska, J.S. Castresana, M.P. Rubio, et al. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma Cancer Res 56 1996 5023 5032
28. H. Wu, V. Goel, and F.G. Haluska PTEN signaling pathways in melanoma Oncogene 22 2003 3113 3122 (Pubitemid 36713763)
29. J. Li, C. Yen, D. Liaw, K. Podsypanina, S. Bose, and S.I. Wang PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer Science 275 1997 1943 1947 (Pubitemid 27148818)
30. P.A. Steck, M.A. Pershouse, S.A. Jasser, W.K. Yung, H. Lin, and A.H. Ligon Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers Nat Genet 15 1997 356 362 (Pubitemid 27147102)
31. M.J. You, D.H. Castrillon, B.C. Bastian, R.C. O'Hagan, M.W. Bosenberg, and R. Parsons Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice Proc Natl Acad Sci U S A 99 2002 1455 1460 (Pubitemid 34136514)
32. B.A. Gilchrest, M.S. Eller, A.C. Geller, and M. Yaar The pathogenesis of melanoma induced by ultraviolet radiation N Engl J Med 340 1999 1341 1348 (Pubitemid 29196597)
33. S. Gandini, F. Sera, M.S. Cattaruzza, P. Pasquini, D. Abeni, and P. Boyle A meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi Eur J Cancer 41 2005 28 44 (Pubitemid 40029657)
34. S. Gandini, F. Sera, M.S. Cattaruzza, P. Pasquini, R. Zanetti, and C. Masini B. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors Eur J Cancer 41 2005 2040 2059 (Pubitemid 41337946)
35. C.J. Hussussian, J.P. Struewing, A.M. Goldstein, P.A. Higgins, D.S. Ally, and M.D. Sheahan Germline p16 mutations in familial melanoma Nat Genet 8 1994 15 21 (Pubitemid 24274055)
36. L. Chin The genetics of malignant melanoma: Lessons from mouse and man Nat Rev Cancer 3 2003 559 570 (Pubitemid 37328828)
37. N.E. Sharpless Ink4a/Arf links senescence and aging Exp Gerontol 39 2004 1751 1759
38. H. Tsao, X. Zhang, K. Kwitkiwski, D.M. Finkelstein, A.J. Sober, and F.G. Haluska Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma Arch Dermatol 136 2000 1118 1122 (Pubitemid 30703748)
39. M. Serrano, G.J. Hannon, and D. Beach A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 Nature 366 1993 704 707 (Pubitemid 24036021)
40. T. Kamijo, J.D. Weber, G. Zambetti, F. Zindy, M.F. Roussel, and C.J. Sherr Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2 Proc Natl Acad Sci 95 1998 8292 8297 (Pubitemid 28326106)
41. J. Pomerantz, N. Schreiber-Agus, N.J. Liegeois, A. Silverman, L. Alland, and L. Chin The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 Cell 92 1998 713 723 (Pubitemid 28155311)
42. G.P. Robertson Functional and therapeutic significance of Akt deregulation in malignant melanoma Cancer Metastasis Rev 24 2005 273 285
43. D.L. Dai, M. Martinka, and G. Li Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases J Clin Oncol 23 2005 1473 1482 (Pubitemid 46260035)
44. B.C. Bastian Understanding the progression of melanocytic neoplasia using genomic analysis: From fields to cancer Oncogene 22 2003 3081 3086
45. J.M. Stahl, A. Sharma, M. Cheung, M. Zimmerman, J.Q. Cheng, and M.W. Bosenberg Deregulated Akt3 activity promotes development of malignant melanoma Cancer Res 64 2004 7002 7010 (Pubitemid 39331010)
46. L.A. Garraway, and W.R. Sellers From integrated genomics to tumor lineage dependency Cancer Res 66 2006 2506 2508
47. E. Steingrimsson, K.J. Moore, M.L. Lamoreux, A.R. Ferré- D'Amaré, S.K. Burley, and D.C. Zimring Molecular basis of mouse microphthalmia (mi) mutations helps explain their developmental and phenotypic consequences Nat Genet 8 1994 256 263 (Pubitemid 24338737)
48. D. Banerjee Genasense Curr Opin Investig Drugs 2 2001 574 580
49. C.R. Goding Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage Genes Dev 14 2000 1712 1728
50. J. Du, A.J. Miller, H.R. Widlund, M.A. Horstmann, S. Ramaswamy, and D.E. Fisher MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma Am J Pathol 163 2003 333 343 (Pubitemid 36759618)
51. A.E. Loercher, E.M.H. Tank, R.B. Delston, and J.W. Harbour MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A J Cell Biol 168 2005 35 40
52. L.A. Garraway, H.R. Widlund, M.A. Rubin, G. Getz, A.J. Berger, and S. Ramaswamy Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma Nature 436 2005 117 122 (Pubitemid 40966196)
53. R.L. Lamason, M.A. Mohideen, J.R. Mest, A.C. Wong, H.L. Norton, M.C. Aros, et al. SLC24A5, a putative cation exchanger, affects pigmentation in zebrafish and humans Science 310 2005 1782 1786
54. R.A. Sturm Skin colour and skin cancer - MC1R, the genetic link Melanoma Res 12 2002 405 416
55. N. Flanagan, E. Healy, A. Ray, S. Philips, C. Todd, and I.J. Jackson Pleiotropic effects of the melanocortin 1 receptor (MC1R) gene on human pigmentation Hum Mol Genet 9 2000 2531 2537 (Pubitemid 30814640)
56. J.S. Palmer, D.L. Duffy, N.F. Box, J.F. Aitken, L.E. O'Gorman, A.C. Green, et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: Is the association explained solely by pigmentation phenotype? Am J Hum Genet 66 2000 176 186
57. C. Bertolotto, P. Abbe, T.J. Hemesath, K. Bille, D.E. Fisher, and J.P. Ortonne Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes J Cell Biol 142 1998 827 835 (Pubitemid 28381498)
58. C.J. Gottardi, and B.M. Gumbiner Adhesion signaling: how beta-catenin interacts with its partners Curr Biol 11 2001 R792 R794
59. F.H. Brembeck, T. Schwarz-Romond, J. Bakkers, S. Wilhelm, M. Hammerschmidt, and W. Birchmeier Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions Genes Dev 18 2004 2225 2230 (Pubitemid 39209569)
60. A.T. Weeraratna, Y. Jiang, G. Hostetter, K. Rosenblatt, P. Duray, and M. Bittner Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma Cancer Cell 1 2002 279 288 (Pubitemid 41039152)
61. M.Y. Hsu, M.J. Wheelock, K.R. Johnson, and M. Herlyn Shifts in cadherin profiles between human normal melanocytes and melanomas J Investig Dermatol Symp Proc 1 1996 188 194
62. J. Qi, N. Chen, J. Wang, and C.H. Siu Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the beta-catenin signaling pathway Mol Biol Cell 16 2005 4386 4397 (Pubitemid 41262905)
63. G. Li, K. Satyamoorthy, and M. Herlyn N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells Cancer Res 61 2001 3819 3825 (Pubitemid 32694999)
64. S. Kuphal, R. Bauer, and A.K. Bosserhoff Integrin signaling in malignant melanoma Cancer Metastasis Rev 24 2005 195 222 (Pubitemid 40922795)
65. E.H. Danen, P.J. Ten Berge, G.N. Van Muijen, A.E. Van 't Hof-Grootenboer, E.B. Brocker, and D.J. Ruiter Emergence of alpha 5 beta1 fibronectin-and alpha v beta 3 vitronectin- receptor expression in melanocytic tumour progression Histopathology 24 1994 249 256
66. P.C. Brooks, S. Stromblad, L.C. Sanders, T.L. von Schalscha, R.T. Aimes, and W.G. Stetler-Stevenson Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3 Cell 85 1996 683 693 (Pubitemid 26181048)
67. B. Felding-Habermann, E. Fransvea, T.E. O'Toole, L. Manzuk, B. Faha, and M. Hensler Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells Clin Exp Metastasis 19 2002 427 436 (Pubitemid 34876210)
68. U.B. Hofmann, J.R. Westphal, E.T. Waas, J.C. Becker, D.J. Ruiter, and G.N. van Muijen Coexpression of integrin alpha(v) beta3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression J Invest Dermatol 115 2000 625 632
69. E. Petitclerc, S. Stromblad, T.L. von Schalscha, F. Mitjans, J. Piulats, and A.M. Montgomery Integrin alpha(v) beta3 promotes M21 melanoma growth in human skin by regulating tumor cell survival Cancer Res 59 1999 2724 2730 (Pubitemid 29269122)
70. X. Li, J. Regezi, F.P. Ross, S. Blystone, D. Ilic', and S.P. Leong Integrin alphavbeta3 mediates K1735 murine melanoma cell motility in vivo and in vitro J Cell Sci 114 2001 2665 2672 (Pubitemid 32734414)
71. G. Fabrizi, and G. Massi Spitzoid malignant melanoma in teenagers: an entity with no better prognosis than that of other forms of melanoma Histopathology 38 2001 448 453 (Pubitemid 32863021)
72. J.M. Mones, and A.B. Ackerman Melanomas in prepubescent children: review comprehensively, critique historically, criteria diagnostically, and course biologically Am J Dermatopathol 25 2003 223 238 (Pubitemid 36706464)
73. J. Wechsler, S. Bastuji-Garin, A. Spatz, C. Bailly, B. Cribier, and L. Andrac-Meyer Reliability of the histopathologic diagnosis of malignant melanoma in childhood Arch Derm 138 2002 625 628 (Pubitemid 34887834)
74. R.L. Barnhill, Z.B. Argenyi, L. From, L.F. Glass, J.C. Maize, and M.C. Mihm Jr Atypical Spitz nevi/tumors: lack of consensus for diagnosis, discrimination from melanoma, and prediction of outcome Hum Pathol 30 1999 513 520 (Pubitemid 29218042)
75. J.M. Mones, and A.B. Ackerman «Atypical» Spitz's nevus, «malignant » Spitz's nevus, and «metastasizing» Spitz's nevus: a critique in historical perspective of three concepts flawed fatally Am J Dermatopathol 26 2004 310 333 (Pubitemid 38989028)
76. R.L. Barnhill The Spitzoid lesion: rethinking Spitz tumors, atypical variants, 'Spitzoid melanoma' and risk assessment Mod Pathol 19 2006 S21 S33
77. J.A. Curtin, J. Fridlyand, T. Kageshita, H.N. Patel, K.J. Busam, and H. Kutzner Distinct sets of genetic alterations in melanoma N Engl J Med 353 2005 2135 2147 (Pubitemid 41653105)
78. G. Palmedo, M. Hantschke, A. Rutten, T. Mentzel, H. Hugel, and M.J. Flaig The T1796A mutation of the BRAF gene is absent in Spitz nevi J Cut Pathol 31 2004 266 270 (Pubitemid 38230570)
79. G. Saldanha, D. Purnell, A. Fletcher, L. Potter, A. Gillies, and J.H. Pringle High BRAF mutation frequency does not characterize all melanocytic tumor types Int J Cancer 111 2004 705 710 (Pubitemid 39062892)
80. D. Mihic-Probst, A. Perren, S. Schmid, P. Saremaslani, P. Komminoth, and P.U. Heitz Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma Anticancer Res 24 2004 2415 2418 (Pubitemid 39166325)
81. M. Gill, J. Cohen, N. Renwick, J.M. Mones, D.N. Silvers, and J.T. Celebi Genetic similarities between Spitz nevus and Spitzoid melanoma in children Cancer 101 2004 2636 2640 (Pubitemid 39532296)
82. D.J. Turner, M.A. Zirvi, F. Barany, R. Elenitsas, and J. Seykora Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction J Cut Pathol 32 2005 334 339 (Pubitemid 40547791)
83. M.C. Van Dijk, M.R. Bernsen, and D.J. Ruiter Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma Am J Surg Pathol 29 2005 1145 1151
84. M. Takata, J. Lin, S. Takayanagi, T. Suzuki, S. Ansai, and T. Kimura Genetic and epigenetic alterations in the differential diagnosis of malignant melanoma and spitzoid lesion Br J Dermatol 156 2007 1287 1294 (Pubitemid 47029852)
85. R. Hay, E. MacRae, D. Barber, M. Khalil, and D.J. Demetrick BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products Arch Pathol Lab Med 131 2007 1361 1367 (Pubitemid 47427589)
86. D.R. Fullen, J.N. Poynter, L. Lowe, L.D. Su, J.T. Elder, and R.P. Nair BRAF and NRAS mutations in spitzoid melanocytic lesions Mod Pathol 19 2006 1324 1332 (Pubitemid 44423079)
87. C.A. La Porta, R. Cardano, F. Facchetti, P. Presicce, S. Rao, and E. Privitera BRAF V599E mutation occurs in Spitz and Reed naevi J Eur Acad Dermatol Venereol 20 2006 1164 1165 (Pubitemid 44425997)
88. J.O. Indsto, S. Kumar, L. Wang, K.A. Crotty, S.M. Arbuckle, and G.J. Mann Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions J Cut Pathol 34 2007 448 455 (Pubitemid 46791200)
89. B.C. Bastian, U. Wesselmann, D. Pinkel, and P.E. Leboit Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma J Invest Dermatol 113 1999 1065 1069 (Pubitemid 30013354)
90. J.L. Maldonado, L. Timmerman, J. Fridlyand, and B.C. Bastian Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway Am J Pathol 164 2004 1783 1787 (Pubitemid 38529780)
91. J.A. Curtin, K. Busam, D. Pinkel, and B.C. Bastian Somatic activation of KIT in distinct subtypes of melanoma J Clin Oncol 24 2006 4340 4346 (Pubitemid 46630793)
92. J.F. Lyons, S. Wilhelm, B. Hibner, and G. Bollag Discovery of a novel Raf kinase inhibitor Endocr Relat Cancer 8 2001 219 225 (Pubitemid 32947644)
93. M.C. Heinrich, C.L. Corless, G.D. Demetri, C.D. Blanke, M. von Mehren, and H. Joensuu Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor J Clin Oncol 21 2003 4342 4349 (Pubitemid 46621810)
94. S.R. Hingorani, M.A. Jacobetz, G.P. Robertson, M. Herlyn, and D.A. Tuveson Suppression of BRAF (V599E) in human melanoma abrogates transformation Cancer Res 63 2003 5198 5202 (Pubitemid 37139827)
95. M. Karasarides, A. Chiloeches, R. Hayward, D. Niculescu-Duvaz, I. Scanlon, and F. Friedlos B-RAF is a therapeutic target in melanoma Oncogene 23 2004 6292 6298 (Pubitemid 39215299)
96. M. Eskandarpour, S. Kiaii, C. Zhu, J. Castro, A.J. Sakko, and J. Hansson Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells Int J Cancer 115 2005 65 73 (Pubitemid 40559669)
97. T. Ahmad, and T. Eisen Kinase inhibition with BAY 43-9006 in renal cell carcinoma Clin Cancer Res 10 2004 6388S 6392S (Pubitemid 39302607)
98. Jallal B. Targeted therapeutics in melanoma: Changing the front end of drug development. Keystone symposia. Advances in the understanding and treatment of melanoma. 2006. Abstract n.° 011. p. 26.
99. K.S. Smalley, N.K. Haass, P.A. Brafford, M. Lioni, K.T. Flaherty, and M. Herlyn Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases Mol Cancer Ther 5 2006 1136 1144 (Pubitemid 43881305)
100. M.A. Tran, R. Gowda, A. Sharma, E.J. Park, J. Adair, M. Kester, et al. Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development Cancer Res 68 2008 7638 7649
101. K.G. Lasithiotakis, T.W. Sinnberg, B. Schittek, K.T. Flaherty, D. Kulms, and E. Maczey Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells J Invest Dermatol 128 2008 2013 2023 (Pubitemid 352001225)
102. K.S. Smalley, M. Xiao, J. Villanueva, T.K. Nguyen, K.T. Flaherty, R. Letrero, et al. CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations Oncogene 28 2009 85 94
103. N. Dumaz, R. Hayward, J. Martin, L. Ogilvie, D. Hedley, and J.A. Curtin In Melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling Cancer Res 66 2006 9483 9491 (Pubitemid 44623646)
104. P.T. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, and V.M. Good Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867 (Pubitemid 38410730)
105. K.S.M. Smalley, K.L. Nathanson, and K.T. Flaherty Genetic subgrouping of Melanoma reveals new opportunities for targeted therapy Cancer Res 69 2009 3141 3244
106. S.M. Wilhelm, C. Carter, L. Tang, D. Wilkie, A. McNabola, and H. Rong BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109 (Pubitemid 39331023)
107. S. Huang, M. Luca, M. Gutman, D.J. McConkey, K.E. Langley, and S.D. Lyman Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential Oncogene 13 1996 2339 2347 (Pubitemid 27026017)
108. S. Ugurel, R. Hildenbrand, A. Zimpfer, P. La Rosée, P. Paschka, and A. Sucker Lack of clinical efficacy of imatinib in metastatic melanoma Br J Cancer 92 2005 1398 1405 (Pubitemid 40705006)
109. J. Lutzky, J. Bauer, and B.C. Bastian Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation Pigment Cell Melanoma Res 21 2008 492 493 (Pubitemid 351990966)
110. F.S. Hodi, P. Friedlander, C.L. Corless, M.C. Heinrich, S. Mac Rae, A. Kruse, et al. Major response to imatinib mesylate in KIT-mutated melanoma J Clin Oncol 26 2008 2046 2051